

March 21, 1964

Dr. William P. Boger
McNeil Laboratories, Inc.
Camp Hill Road
Fort Washington, Pa.

Dear Bill:

Thank you very much for your letter regarding Dr. Horst Flegel. My secretary sends you her apologies, and to these I add my own, for I should have found the error before I signed the document. Please forgive both of us.

I am awaiting a response from Dr. Flegel, and look forward to having him join us later on this year.

May I impose on you to consider another matter? During the past few weeks, the staff of the Institute have discussed the possibility of establishing an ECDEU similar to those established through the NIH Clinical Committee. It is my intention to set aside a few beds in the Institute and match these by beds at the St. Louis State Hospital, for studies of compounds which may be suitable in the populations ordinarily found in a state hospital. Whether such a unit would be helpful, is a question. Among the compounds which my associates have discussed is one produced by McNeil, Triperidol.

Has this compound been approved by the FDA, and is it now commercially available? If not, what is its present status? Is it still an investigational compound?

In either case, does McNeil Laboratories have any interest at the present in expanding its studies of this compound, either in a clinical program, or possibly in the specialized EEG-behavioral correlations which George Ulett, Turan Itil and I are so interested?

Thank you very much for your cooperation.

Sincerely yours,

Max Fink, M.D.
Director

MF/jb